Sanofi and GSK progress talks with EU for 300 million COVID-19 vaccines
Sanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreSanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read moreThe Chinese company Clover Biopharmaceuticals revealed the start of a randomized, double-blind, human stage Phase I placebo-controlled clinical study to
Read moreAstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read moreScientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read moreSwiss pharma giant Roche has received Emergency Use Authorisation (EUA) from the FDA for its latest COVID-19 antibody test –
Read moreModerna, a clinical-stage biotech developing messenger RNA (mRNA) therapeutics and vaccines, and Swiss pharma giant Lonza today announced the introduction
Read moreARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine
Read more